Edition:
United Kingdom

People: Dynavax Technologies Corp (DVAX.OQ)

DVAX.OQ on NASDAQ Stock Exchange Capital Market

3.78USD
26 Jun 2019
Change (% chg)

-- (--)
Prev Close
$3.78
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
352,195
52-wk High
$16.30
52-wk Low
$3.58

Ostrach, Michael 

Mr. Michael S. Ostrach serves as Chief Financial Officer, Senior Vice President, Chief Business Officer of the Company. Mr. Ostrach joined Dynavax in October 2006 as Vice President, Chief Business Officer and General Counsel, and became Principal Financial Officer in September 2013, Chief Financial Officer in March 2015 and Senior Vice President in February 2016. Mr. Ostrach held the position of Dynavax’s General Counsel from October 2006 to September 2015. From 2005 to 2006, he was Chief Operating Officer, Chief Financial Officer and General Counsel at Threshold Pharmaceuticals. From 1997 to 2004, Mr. Ostrach was at Kosan Biosciences, most recently as President and Chief Operating Officer. Mr. Ostrach began his corporate career at Cetus Corporation, where he served in several capacities between 1981 and 1991, initially as General Counsel and finally as Senior Vice President of Corporate Affairs and General Counsel. Following the acquisition of Cetus by Chiron Corporation in 1991, Mr. Ostrach became President of Chiron Technologies. He holds a B.A. from Brown University and a J.D. from Stanford Law School.

Basic Compensation

Total Annual Compensation, USD 439,875
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 3,122,640
Fiscal Year Total, USD 3,562,510

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Arnold Oronsky

231,767

David Novack

1,697,590

Ryan Spencer

--

Eddie Gray

4,748,840

Michael Ostrach

3,562,510

Robert Coffman

3,628,280
As Of  31 Dec 2018